Xilio Therapeutics (NASDAQ:XLO – Get Free Report) and Indivior (NASDAQ:INDV – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
Profitability
This table compares Xilio Therapeutics and Indivior’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xilio Therapeutics | N/A | -153.48% | -89.26% |
| Indivior | 0.44% | 842.72% | 12.42% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Xilio Therapeutics and Indivior, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xilio Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Indivior | 0 | 0 | 2 | 0 | 3.00 |
Volatility and Risk
Xilio Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
Insider & Institutional Ownership
54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 5.2% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Xilio Therapeutics and Indivior’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xilio Therapeutics | N/A | N/A | -$76.40 million | ($2.57) | -0.34 |
| Indivior | $1.12 billion | 1.87 | $2.00 million | $0.01 | 1,526.00 |
Indivior has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Summary
Indivior beats Xilio Therapeutics on 11 of the 12 factors compared between the two stocks.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
